Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) today announced that Health Canada has issued cannabis Research and Development (“R&D”) license LIC-7NONT76UNW-2019 to its subsidiary, Lexaria CanPharm ULC. According to the update, the license, which carries a four-year term unless renewed, is effective immediately and will allow one of the country’s newest and most advanced formulation laboratories to conduct extensive investigatory work in THC and CBD delivery using optimized, proprietary formulations and techniques. The purpose-built laboratory is permitted at local and federal levels and fully outfitted to produce DehydraTECH(TM) infusions and includes two different methodologies by which the company can create nano-sized molecules when deemed beneficial. “Receipt of our R&D License from Health Canada will allow us to implement and complete investigatory studies significantly more rapidly now, than at any previous time in our Company’s history,” Lexaria President and Chief Scientist John Docherty said in the news release. “This license will greatly enhance our ability to work with cannabis Licensed Producers to perform work in-house on customized formulations that could benefit each of Canada’s licensed cannabis companies.”
To view the full press releases, visit http://cnw.fm/CLos3
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH(TM) delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Do you have a questions or are you interested in working with CNW? Ask our Editor